BC Week In Review | Jan 11, 2019
Clinical News

Aevi's AEVI-001 misses in Phase II for children with ADHD

Aevi Genomic Medicine Inc. (NASDAQ:GNMX) said AEVI-001 missed the primary endpoint in both Parts A and B of the Phase II ASCEND trial to treat ADHD in patients ages 6-17. The company plans to conduct...
BC Week In Review | Mar 23, 2017
Clinical News

AEVI-001: Ph II/III SAGA data

Top-line data from the double-blind, U.S. Phase II/III SAGA trial in 96 evaluable ADHD patients ages 12-17 with genetic disorders impacting mGluRs showed that twice-daily oral AEVI-001 missed the primary endpoint of reducing ADHD-RS total...
BC Extra | Mar 20, 2017
Clinical News

Aevi plummets after ADHD candidate fails in Phase II/III

Aevi Genomic Medicine Inc. (NASDAQ:GNMX) shed $3.23 (59%) to $2.21 on Monday after it said AEVI-001 missed the primary endpoint in the Phase II/III SAGA study to treat ADHD in adolescent patients with metabotropic glutamate...
BC Week In Review | Feb 1, 2017
Clinical News

AEVI-001: Ph I/II started

Aevi began an open-label, U.S. Phase I/II trial evaluating 50, 100, 200 and 400 mg oral AEVI-001 twice daily over 5 weeks in about 12 patients ages 12-17 with a 22q11.2 deletion and diagnosed with...
BioCentury | Oct 3, 2016
Finance

ASH and others

Cancer and hematology companies are likely to garner the most headlines in 4Q16 thanks to ESMO in October and ASH in December, but some investors also are branching out to events that typically receive less...
BC Week In Review | Jun 27, 2016
Clinical News

NFC-1: Phase II/III started

Medgenics began the double-blind, placebo-controlled, U.S. Phase II/III SAGA trial to evaluate 100, 200 and 400 mg oral NFC-1 twice daily for 6 weeks in 90 patients ages 12-17. In 1H17, Medgenics plans to start...
BC Innovations | May 26, 2016
Targets & Mechanisms

Dissociating ketamine

For decades, researchers have struggled with the conundrum of how to exploit the antidepressant effects of ketamine without incurring its psychedelic effects. Now, a group from NIH and the University of Maryland has shown that...
BC Innovations | Mar 3, 2016
Targets & Mechanisms

Rescue mission

A pair of preclinical studies published last month on the autism target SHANK3 provide what might be the most meaningful progress for patients since the gene was linked with the disease over a decade ago....
BioCentury | Mar 2, 2015
Finance

Prexton's PD inflection

Prexton Therapeutics S.A. became the first spinout from Merck Serono S.A .'s Entrepreneur Partnership Program to raise follow-on funding with the close of its €8.7 million ($9.9 million) series A round last week. The cash...
BioCentury | Aug 20, 2012
Emerging Company Profile

Mind-NRG: New neuroprotection

Approved therapies for Parkinson's disease treat motor symptoms but cannot stop the loss of dopaminergic neurons that causes them. Mind-NRG 's neuregulin 1 fragment could slow disease progression by preventing damage to dopaminergic neurons before...
Items per page:
1 - 10 of 52